Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PureBMC
- Development stage
- Unknown
- Lead developer
- Emcyte
- Modality
- Cell Therapies
- Administration
- Injection, Topical
01
Overview
PureBMC is a point-of-care bone marrow concentrating system developed by EmCyte Corporation. It is designed to process bone marrow aspirate (BMA) through density gradient centrifugation to produce a high-concentration bone marrow concentrate (BMC). The system effectively isolates and concentrates regenerative cells, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and total nucleated cells (TNCs), while significantly reducing red blood cell and granulocyte contamination. PureBMC is primarily utilized in regenerative medicine and orthopedic procedures to facilitate tissue repair and healing by delivering a concentrated dose of autologous growth factors and progenitor cells to the site of injury. The resulting concentrate contains a rich milieu of cytokines and growth factors such as PDGF, TGF-beta, and VEGF, which contribute to its therapeutic efficacy in bone grafting and soft tissue repair.
- Brand names
- PureBMC
- Other names
- PureBMC Bone Marrow Concentrating SystemPureBMC BMA Concentrating System
Beyond the preview
Go deeper on PureBMC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PureBMC.